Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic
liver disease worldwide, affecting up to~ 30% of adult populations. NAFLD defines a …

Kidney disease is a leading cause of morbidity and mortality across the globe. Current
interventions for kidney disease include dialysis and renal transplantation, which have …

Background Excess aldosterone accelerates chronic kidney disease progression. This
phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy …

Objectives The purpose of this investigation was to analyze the prevalence of apical
periodontitis (AP) and periodontal disease (periodontitis)(PD) in Chronic kidney disease …

Background Chronic kidney disease (CKD) involves a variety of pathological processes, and
ferroptosis plays a vital role in CKD progression. Targeting ferroptosis is a promising …

Renal fibrosis is a common pathological outcome of various chronic kidney diseases, and as
yet, there is no specific treatment. Dapagliflozin has shown renal protection in some clinical …

Background Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are part of the standard
of care for patients with chronic kidney disease (CKD), both with and without type 2 diabetes …

The kidney has high bioenergetic needs, renal cells are rich in mitochondrial content
containing 100s to 1000s of mtDNA molecular per cell. MtDNA has emerged as both a …

Patients with kidney failure (KF) receiving maintenance hemodialysis (HD) experience
numerous symptoms that impair their health-related quality of life (HRQOL) and contribute to …

Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD). In
addition to traditional risk factors, such as hypertension, dyslipidemia, diabetes and …